Fourteen-Day Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop-14): Use It Right or Do Not Use It at All

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2011.647316
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Accept: A Phase Ib/Ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-Chop) for Patients With Diffuse Large B-Cell Lymphoma (Dlbcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Seamless Care, Do It Well or Not at All

International Journal of Clinical Pharmacy
ToxicologyPharmacyPharmacologyPharmaceutical Science
2019English

Comments on "Why Not Use It All?".

Environmental Health Perspectives
MutagenesisPublic HealthEnvironmentalHealthToxicologyOccupational Health
1999English

SWOT: What Is It All About and How Do You Use It?

British Journal of Healthcare Assistants
2018English

Commentary: Use It or Lose It

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2019English

It's Our Convention: Use It or Lose It?

Disability, CBR & Inclusive Development
2012English

Is It Legal? Is It Right? The Can and Should of Use

IEEE Security and Privacy
Computer NetworksElectronic EngineeringLawElectricalCommunications
2016English

The Elevation of Cardio-Ankle Vascular Index in a Patient With Malignant Lymphoma Treated With a Combination Therapy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone

Journal of Clinical Medicine Research
2017English

Use It or Lose It: Cerebral Perfusion and Aortic Arch Surgery

Journal of Thoracic and Cardiovascular Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy